亨利香恩服务 2024年度报告

A MESSAGE FROM THE CHAIRMAN OF THE BOARDAND CHIEF EXECUTIVE OFFICER protective equipment category and COVID test kitsales, and the cyber incident, we remain confidentin the underlying strength of our business. To My Fellow Stakeholders, Last year we reported that Henry Schein wasworking tirelessly to uphold our brand promise- Rely On Us – following some disruption to ouroperations in the fourth quarter of 2023. Thanksto the relentless efforts of Team Schein, during2024 we successfully achieved this goal, re-engaging with our customers, delivering high levelsof customer service and satisfaction, and we arenow looking ahead with a commitment to growour business from the strong base we have built. Financial Results** Our 2024 results reflect stable end markets andsequential market share gains. Total net salesreached $12.7 billion, an increase of 2.7% from 2023.GAAP net income was $390 million, or $3.05 perdiluted share, compared to $416 million, or $3.16per diluted share, in 2023. Non-GAAP net incomeincreased to $605 million, or $4.74 per diluted share,versus $593 million, or $4.50 per diluted share,in 2023. Operating cash flow in 2024 was $848million, compared to $500 million in 2023, and wemade strategic acquisitions including investmentsin non-controlling interests of $485 million, andcompleted $385 million in stock repurchases. We continued to make progress throughout the yearon our recently completed 2022–2024 BOLD+1Strategic Plan, exceeding our 2024 target ofgenerating 40% of our worldwide operating incomefrom high-growth, high-margin businesses. BOLD+1has become the foundation of our transformation intoa higher growth, higher margin, customer-centric,digitally advanced and more agile and efficientcompany, with the opportunity to further leveragesynergies across our complementary businesses. We are pleased with the performance of our recentstrategic acquisitions as well as the successfullaunch of certain internally developed productsand services. This includes the Tapered ProConical dental implant in the U.S., developed andmanufactured by our BioHorizons subsidiary, whichsignificantly expands the U.S. market we are ableto serve. There were also new developmentsto enhance the functionality of our Dentrix® andDentrix Ascend® practice management softwaresolutions. This includes Eligibility Pro software,providing practices important patient informationon insurance coverage, and Reserve with Google,providing functionality for patients to book a dentalappointment directly from Google’s Chrome browser. For the full-year 2024, our high-growth, high-margin businesses accounted for approximately41% of our total operating income. Including incomefrom our corporate brand product offerings, thisincreases to approximately 50% of total operatingincome and almost $3 billion, or 25%, of oursales. Henry Schein has a strong track record ofdelivering double-digit earnings growth, with anon-GAAP earnings per share (EPS) compoundannual growth rate of 12.4%*since our IPO. Whilerecently we have faced several headwinds, includingmacroeconomic pressures, volatility in the personal Our BOLD+1 Strategy: StrengtheningOur Competitive Advantage The BOLD+1 strategy, as a brief reminder, involvesBuildingcomplementary software, specialty,and services businesses for high growth;Operationalizingour One Distribution approach to A New Era deliver an exceptional customer experience, andincrease efficiency, and growth;Leveragingallof Henry Schein’s businesses and solutions tobroaden and deepen customer relationships; andDrivingdigital transformation for our customers andfor Henry Schein. In doing so, we believe that byexecuting on these pillars we deliver differentiatedsolutions that make our customers’ practices moresuccessful and improve patient outcomes. To continue to advance our strategy, we havestreamlined our organizational structure into twogroups to oversee our businesses. We namedAndreaAlbertinito the position of CEO, Global Distributionand Technology, overseeing the further integrationof our distribution, value-added services, andtechnology solutions businesses.Tom Popeck, asCEO of the Henry Schein Products Group, will leada group of businesses, including dental implants,biomaterials, endodontics, orthodontics, orthopedics,as well as the Henry Schein-brand product portfolio.We believe these changes will enhance growthby expanding our product and service offerings,strengthening our e-commerce business, andimproving operational efficiencies. Along with thisnew organizational structure, we have also updatedour reportable segments to align with the newmanagement reporting, thereby providing clearer line-of-sight into our business performance for investors. In 2024, some of our key accomplishments included: • Buildingon our leadership in global dentalsoftware, endodontics, and implants. We alsoentered the extremities niche of the attractiveorthopedic market through the acquisition ofTriMed, providing solutions for the orth